bjective To study the change of mucins of expression in lithic cholecystitis and cholecystic adenomatiod polyps. MethodsMUC1 and MUC3 were detected in the mucosa of human normal gallbladders (20 cases, control group), of calcareous cholecystitis (38 cases, calcareous group) and of adenomatoid polyps (18 cases, polyp group) with immunohistochemical stains and Western blotting methods. ResultsThe positive rate and optical density values of MUC1 were increased significantly in calcareous and polyp group vs control group (P＜0.01), otherwise, MUC3 was decreased markedly (P＜0.01). Conclusion The expressions of MUC1, MUC3 were not synchronization in different lesions of cholecyst.
To observe the pathologic changes of normal tissue in nude mice after peritoneal perfusion with hyperthermia, hyper-osmolar solution and mitomycin C (MMC). Fifty BALB/c nunu mices (7-10 weeks old) bearing HT-2 lines were chosen for the study, and were randomly divided into five groups: isotonic solution (control group), hyperosmolar solution (HOS group), HOS plus MMC group, hyperthermia (HT group) and HOS plus HT plus MMC group. After continuous hyperthermic peritoneal perfusion (42℃/30min) with 7.5% NaCl and 5μg/ml MMC, the liver, spleen, small intestine and kidney were examined by light microscopy. Results: ①In HOS and HOS plus MMC groups, no changes of liver, spleen and kidney were found. ②In HT and HOS plus HT plus MMC groups, slight degeneration of liver, hyperemia of spleen, swelling of kidney tubule cells and small intestine were found. ③In HOS plus HT plus MMC group, partial loss of small intestinal villi were also observed. Conclusioin: After continuous hyperthermic perfusion conbined with hyper-osmolar solutions and mitomycin C, a slight injury was showed in normal tissue of nude mice.
Objective To evaluate the effectiveness of PTD regimen (pamidronate disodium + thalidomide + dexamethasone) and TD regimen (thalidomide + dexamethasone) in the treatment of multiple myeloma. Methods The patients meeting the inclusion criteria were randomly treated with PTD and TD regimens from January 2004 to December 2008. The effectiveness and safety of the two groups were observed after 8 weeks and the statistical analyses were performed using SPSS 13.0 software. Results A total of 25 patients were included, of which 13 were treated with PTD regimen and the other 12 were treated with TD regimen. The results showed overall response rates were 84.6% and 83.3% in the PTD and TD groups, respectively, with no significant difference (Pgt;0.05). The complete response rate (5/13 vs. 1/12) and early response rate (within 2 weeks, 4/13 vs. 1/12) for bone pain in the PTD group were better than those of TD group (Plt;0.05). Conclusion Compared with TD regimen, PTD regimen has more dramatic and faster effects on bone pain relief for multiple myeloma, but for overall response rate, further larger sample size randomized controlled trials are needed.